Your browser doesn't support javascript.
The global impact of SARS-CoV-2 in 181 people with cystic fibrosis.
McClenaghan, Elliot; Cosgriff, Rebecca; Brownlee, Keith; Ahern, Susannah; Burgel, Pierre-Régis; Byrnes, Catherine A; Colombo, Carla; Corvol, Harriet; Cheng, Stephanie Y; Daneau, Géraldine; Elbert, Alexander; Faro, Albert; Goss, Christopher H; Gulmans, Vincent; Gutierrez, Hector; de Monestrol, Isabelle; Jung, Andreas; Justus, Lutz Nährlich; Kashirskaya, Nataliya; Marshall, Bruce C; McKone, Edward; Middleton, Peter G; Mondejar-Lopez, Pedro; Pastor-Vivero, M Dolores; Padoan, Rita; Rizvi, Samar; Ruseckaite, Rasa; Salvatore, Marco; Stephenson, Anne L; Filho, Luiz Vicente R da Silva; Melo, Joel; Zampoli, Marco; Carr, Siobhán B.
  • McClenaghan E; Cystic Fibrosis Trust, UK CF Registry, 1 Aldgate, London EC3N 1RE, UK. Electronic address: elliot.mcclenaghan@cysticfibrosis.org.uk.
  • Cosgriff R; Cystic Fibrosis Trust, UK CF Registry, 1 Aldgate, London EC3N 1RE, UK.
  • Brownlee K; Cystic Fibrosis Trust, UK CF Registry, 1 Aldgate, London EC3N 1RE, UK.
  • Ahern S; Monash University, Melbourne, Australia.
  • Burgel PR; Université de Paris, Inserm U1016, Institut Cochin and Cochin Hospital, Assistance Publique Hôpitaux de Paris (APHP), France.
  • Byrnes CA; Starship Children's Hospital and University of Auckland, Auckland, New Zealand.
  • Colombo C; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
  • Corvol H; Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, Assistance Publique Hôpitaux de Paris (APHP), Hôpital Trousseau, Service de Pneumologie Pédiatrique, Paris, France.
  • Cheng SY; Cystic Fibrosis Canada, Canada.
  • Daneau G; Sciensano, Belgium.
  • Elbert A; Cystic Fibrosis Foundation, USA.
  • Faro A; Cystic Fibrosis Foundation, USA.
  • Goss CH; University of Washington, Seattle, USA.
  • Gulmans V; Dutch CF Foundation NCFS, Baarn, Netherlands.
  • Gutierrez H; University of Alabama at Birmingham, Alabama, USA.
  • de Monestrol I; Stockholm CF Center, Sweden.
  • Jung A; University Children's Hospital Zurich, Switzerland.
  • Justus LN; Department of Pediatrics, Justus-Liebig-University Giessen, Giessen, Germany.
  • Kashirskaya N; Research Centre for Medical Genetics, Russia.
  • Marshall BC; Cystic Fibrosis Foundation, USA.
  • McKone E; St Vincent's University Hospital, Dublin, Ireland.
  • Middleton PG; Westmead Hospital, Sydney, Australia.
  • Mondejar-Lopez P; Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.
  • Pastor-Vivero MD; Hospital Universitario Cruces, Bizkaia, Spain.
  • Padoan R; Cystic Fibrosis Support Center, Department of Paediatric, University of Brescia, Italy.
  • Rizvi S; Cystic Fibrosis Foundation, USA.
  • Ruseckaite R; Monash University, Melbourne, Australia.
  • Salvatore M; National Center Rare Diseases Undiagnosed Rare Diseases Interdepartmental Unit Istituto Superiore di Sanità, Rome, Italy.
  • Stephenson AL; Cystic Fibrosis Canada, Canada; Toronto Adult Cystic Fibrosis Centre, St. Michael's Hospital, Toronto, Canada.
  • Filho LVRDS; Instituto da Criança HCFMUSP, São Paulo, Brazil.
  • Melo J; Instituto Nacional del Tórax, Chile.
  • Zampoli M; University of Cape Town and Red Cross War Memorial Children's Hospital, South Africa.
  • Carr SB; Royal Brompton Hospital and Imperial College London, UK.
J Cyst Fibros ; 19(6): 868-871, 2020 11.
Article in English | MEDLINE | ID: covidwho-907134
ABSTRACT
With the growing SARS-CoV-2 pandemic, we need to better understand its impact in specific patient groups like those with Cystic Fibrosis (CF). We report on 181 people with CF (32 post-transplant) from 19 countries diagnosed with SARS-CoV-2 prior to 13 June 2020. Infection with SARS-CoV-2 appears to exhibit a similar spectrum of outcomes to that seen in the general population, with 11 people admitted to intensive care (7 post-transplant), and 7 deaths (3 post-transplant). A more severe clinical course may be associated with older age, CF-related diabetes, lower lung function in the year prior to infection, and having received an organ transplant. Whilst outcomes in this large cohort are better than initially feared overall, possibly due to a protective effect of the relatively younger age of the CF population compared to other chronic conditions, SARS-CoV-2 is not a benign disease for all people in this patient group.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Lung Transplantation / Cystic Fibrosis / SARS-CoV-2 / COVID-19 / Hospitalization Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Adult / Aged / Female / Humans / Male Language: English Journal: J Cyst Fibros Year: 2020 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Lung Transplantation / Cystic Fibrosis / SARS-CoV-2 / COVID-19 / Hospitalization Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Adult / Aged / Female / Humans / Male Language: English Journal: J Cyst Fibros Year: 2020 Document Type: Article